Overview

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Status:
Completed
Trial end date:
2017-01-12
Target enrollment:
Participant gender:
Summary
This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI. Imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. Determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Michael Iv
Collaborator:
National Cancer Institute (NCI)
Treatments:
Ferrosoferric Oxide